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Abstract
Background: To investigate the relationship between the magnetic resonance imaging (MRI) features of breast
cancer and its clinicopathological and biological factors.
Methods: Dynamic MRI parameters of 68 invasive breast carcinomas were investigated. We also analyzed
microvessel density (MVD), estrogen and progesterone receptor status, and expression of p53, HER2, ki67, VEGFR-1
and 2.
Results: Homogeneous enhancement was significantly associated with smaller tumor size (T1: < 2 cm) (p = 0.015).
Tumors with irregular or spiculated margins had a significantly higher MVD than tumors with smooth margins (p =
0.038). Tumors showing a maximum enhancement peak at two minutes, or longer, after injecting the contrast, had
a significantly higher MVD count than those which reached this point sooner (p = 0.012). The percentage of
tumors with vascular invasion or high mitotic index was significantly higher among those showing a low
percentage (≤ 150%) of maximum enhancement before two minutes than among those ones showing a high
percentage (>150%) of enhancement rate (p = 0.016 and p = 0.03, respectively). However, there was a significant
and positive association between the mitotic index and the peak of maximum intensity (p = 0.036). Peritumor
inflammation was significantly associated with washout curve type III (p = 0.042).
Conclusions: Variations in the early phase of dynamic MRI seem to be associated with parameters indicatives of
tumor aggressiveness in breast cancer.
Background
Magnetic resonance imaging (MRI) plays an important
role in the evaluation of the extent of breast cancer by
revealing multifocal tumor growth in patients who are
candidates for conservative breast surgery [1]. MRI per-
mits us to explorer two concepts: First, we are able to
analyze the morphologic characteristics of the lesions
with high spatial resolution, such as the margin mor-
phology (smooth, irregular or spiculated) or the internal
architecture of the tumors (represented as internal mass
enhancement: homogeneous, heterogeneous or rim
enhancement) [1-3]. Second, we can also obtain
dynamic data derived from the kinetic patterns of lesion
enhancement after the administration of contrast mate-
rial [4]. These latter MRI parameters include the beha-
viour of the signal intensity in the early phase after the
administration of contrast material, as well as in the late
postcontrast period. Likewise, this time course may be
visualized in two and three-dimensional dynamic MRI
series. These time-signal intensity curves allow us to
determine whether the signal intensity continues to
increase after the initial upstroke, cuts off and reaches a* Correspondence: investigacion@hospitaldejove.com
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plateau, or if it just washes out. It has been demon-
strated that this latter curve type is a strong indicator of
malignancy, being independent of other criteria [5].
More recently, MRI appears to have an important
value in estimating other aspects of interest in breast
cancer, such as the assessment of axillary lymph node
metastasis, or the prediction of the clinicopathological
response to primary chemotherapy [3,6,7]. It has also
been suggested that MRI might be useful in predicting
the disease-free survival in breast cancer patients [8]. In
addition, there are studies indicating that dynamic con-
trast-enhanced MRI help to predict prognostic factors
and biological activity of breast cancer by revealing mor-
phological features and enhancement parameters of the
primary tumors, such as angiogenesis, degree of fibrosis
[9], histological grade [10,11], negative expression of
estrogen repeptor and progesterone receptor [11], vascu-
lar endothelial growth factor (VEGF) expression [9] or
HER-2 overexpression [12]. In this context, the objec-
tives of this study were to investigate the relationship
between the MRI features of breast cancer and some
other of their clinicopathological and biological charac-
teristics, such as vascular invasion, peritumoral inflam-
mation or VEGF-receptor-1 and 2.
Methods
Patient selection and characteristics
This study comprised 68 women consecutively diag-
nosed of early invasive breast cancer (without distant
metastasis at time of initial diagnoses) and treated
between 1999 and 2006. Initially, the lesions were
detected by physical examination, mammography, or
ultrasonography. All of the women did not receive any
type of neoadjuvant therapy. In addition, for the 68
cases we obtained sufficient tissue in the paraffin blocks
used for manufacturing the tissue arrays (TAs). The
patients’ age ranged from 30 to 83 years (mean, 55.5
years), and the tumor size between 0.6 cm and 12 cm
(mean, 2.3 cm). A total of 54 tumors were of the ductal
type, 9 of the lobular type, 2 mucinous, one medullar,
one tubullar and one papilla. Other patient characteris-
tics evaluated in this study are listed in Table 1. The
histologic grade was assessed according to criteria
reported by the Nottingham modification of Bloom and
Richardson score (SBR) [13]. DCIS component was pre-
sent in 16 cases (23.5%)
Women were treated according to the International
European Guidelines. The study adhered to national
regulations and was approved by our institution’s Ethics
and Investigation Committee.
MR Imaging
All studied subjects had exactly the same MR sequences
and parameters. MRI was performed at 1.5 Teslas
(Echospeed Signa; General Electric Medicale Systems,
Milwaukee, WI, USA). After the informed consent was
obtained, patients were placed in the prone position and
examined using standard dedicated bilateral breast coils.
The imaging protocol consisted of an initial scout view
that provided axial, coronal, and sagittal images of both
breast. These images were used to exactly localize the
spatial distribution of the breast parenchymal volume.
The subsequent axial dynamic series were then posi-
tioned to cover the whole parenchyma.
Before administration of contrast material, T1-
weighted frames were acquired in the axial plane
(FSPGR -fast spoiled gradient echo- 3D; FA -flip angle-,
10°; TR, 9.9 milliseconds; TE, 4.2 milliseconds; NEX, 1;
2-3 mm slice thickness with no gap; 512 × 192 matrix;
in-plane resolution, 0.6 × 1.8; frequency was in the ante-
roposterior direction). Acquisition of dynamic imaging
started 10s after the intravenous injection of 0.2 mmol
per kilogram body weight of gadopentetate dimeglumine
(Gd-DTPA) (Magnevist; Schering, Madrid, Spain), fol-
lowed by a 20 ml saline solution flush, at an injection
rate of 2 mL/s, following by six series, with lasted 80s
each for a total imaging time of slightly over nine min-
utes. The injection unit contained no magnetic compo-
nents and operated with pressurized air. Imaging time
with this frame was approximately 80s for a total ima-
ging time of slightly over nine minutes. Acquisition of
dynamic imaging started 10s after contrast injection, fol-
lowing by six frames. Each frame had 64 slices.
Image Analysis
All images were evaluated with the Functool algorithm
on the Advantage Windows Workstation (General Elec-
tric Medical Systems) by consensus between two radiol-
ogists (O.F.G. and P.G.P.), with a wide experience in
breast imaging.
After the dynamic series were obtained, image sub-
traction was performed to suppress the fat signal, and
enhancing lesions were identified on the subtracted
images. To verify the presence of a contrast-enhancing
lesion and to exclude subtraction artifacts, we also re-
identified the lesions on the non-subtracted images.
For each suspected lesion included in the dynamic
slices, the following morphologic features were recorded:
site, size, margins, and type of enhancement. To evalu-
ate kinetics, a small region of interest (ROI) is placed
selectively over the most intensely enhancing area of the
lesion. The ROI size was always greater than three pix-
els, and without upper limit. The ROI was placed in the
rim enhancement during the dynamic study, when the
tumors showed this finding.
The lesion margins were described as well-defined
(regular) or ill-defined (irregular or spiculated). The
enhancement after Gd-DTPA administration was classi-
fied as homogeneous, heterogeneous, or rim
enhancement.
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Quantitative analysis of Gd-DTPA uptake was based
on a two-compartment model of the pharmacokinetic
behaviour of contrast medium according to three para-
meters: wash-in rate, wash-out rate and amplitude of
uptake. The enhancement rate was calculated according
to the following enhancement formula: enhancement
rate = [(SIpost - SIpre)/SIpre] × 100 (%), where SIpre and
SIpost are the precontrast and the postcontrast signal
intensities, respectively [5]. According to the most com-
monly accepted criteria, signal-intensity curves were
classified into three categories: persistent enhancement
(type I), plateau (type II) and washout (type III). Plateau
and wash-out curves showed the peak of enhancement
within the early phase of contrast administration. Pla-
teau curves leveled off, whereas wash-out curve demon-
strated a decrease in signal intensity after reaching a
maximum signal intensity value. The following para-
meters of the dynamic signal before Gd-DTPA adminis-
tration were also considered: peak of maximum
intensity before 2 minutes, within 2 to 4 minutes
(including 2 and 4 minutes), within 4 to 6 minutes (>4
minutes and 6 minutes inclusived), and after 6 minutes;
percentage of maximum uptake before 2 minutes (three
groups: <100%, 100%-150%, and >150%); median (range)
of the maximum uptake value before 2 minutes; and the
median (range) time to reach the maximum uptake.
Tissue arrays and immunohistochemistry
Routinely fixed (overnight in 10% buffered formalin),
paraffin-embedded tumor samples stored in our pathol-
ogy laboratory files were used in this study. Histopatho-
logically representative tumor areas were defined on
haematoxylin and eosin-stained sections and marked on
the slide. Tumor tissue array blocks were obtained by
punching a tissue cylinder (core) with a diameter of 1.5
mm through a histologically representative area of each
‘donor’ tumor block, which was then inserted into an
empty ‘recipient’ tissue array paraffin block using a
manual tissue arrayer (Beecher Instruments, Sun Prairie,
WI, USA). Areas of non-necrotic cancerous tissue from
tumoral center were selected for arraying by an experi-
enced pathologist (L.O.G.). Two cores were used for
each case. From the 68 tumor samples available, two tis-
sue array blocks were prepared, each containing more
than 30 samples, as well as internal controls including
four normal breast tissue samples from two healthy
women that underwent reductive mammary surgery.
Serial 5-μm sections were consecutively cut with a
microtome (Leica Microsystems GmbH, Wetzlar, Ger-
many) and transferred to adhesive-coated slides. One
section from each tissue array block was stained with
Haematoxylyn and eosin, and these slides were then
reviewed to confirm that the sample was representative
of the original tumor. Immunohistochemistry was done
on these sections of tissue arrays (TA) using a
TechMate TM50 autostainer (Dako, Glostrup, Den-
mark). Sections were then incubated with the following
(all from Dako): mouse anti-ER clone 1D5 at a dilution
of 1/50, anti-PR clone PgR 636 at a dilution of 1/50,
anti-Ki67 clone MIB-1 at a dilution of 1/50, anti-p53
clone DO-7 at a dilution of 1/75 and rabbit policlonal
anti-HER-2/neu oncoprotein at a dilution of 1/250,
mouse anti-CD34 (clone QBEnd/10 at dilution 1:1) (Lab
Vision Corporation, Fremont CA, USA), rabbit anti Flt
-1/VEGFR-1 (dilution 1:1), and Flk1/KDR/VEGFR-2
(dilution 1:1) (Lab Vision Corporation, Fremont, CA,
USA); all the dilutions were made in Antibody Diluent,
(Dako) for 30 min at room temperature.
Tissue sections were deparaffinized in xylene, and
then rehydrated in graded concentrations of ethyl alco-
hol (100%, 96%, 80%, 70%, then water). To enhance
antigen retrieval for some antibodies, TA sections were
microwave-treated (H2800 Microwave Processor, EBS-
ciences, East Granby, CT, USA) in citrate buffer (Target
Retrieval Solution, Dako) at 99°C for 16 min. Endogen-
ous peroxidase activity was blocked by incubating the
slides in peroxidase-blocking solution (Dako) for 5 min.
The EnVision Detection Kit (Dako) was used as the
staining detection system. Sections were counterstained
with hematoxilin, dehydrated with ethanol, and perma-
nently coverslipped.
TA analysis
For VEGFR-1 and 2, the location of immunoreactivity,
as well as the percentage of stained cells and their inten-
sity, were determined. All the cases were semiquantified
for each protein-stained area. An image analysis system
with the Olympus BX51 microscope and Soft analysis
(analySIS®, Soft imaging system, Münster, Germany)
were used as follows: tumor sections were stained with
antibodies according to the method explained above and
counterstained with haematoxylin. There were different
optical thresholds for both stains. Each core was
scanned with a 400 × power objective in two fields per
core. Fields were selected by searching for the highest
staining area and finally we average the staining score.
The computer program selected and traced a line
around antibody-stained areas (higher optical threshold:
red spots), with the remaining, non-stained areas (hae-
matoxylin-stained tissue with lower optical threshold)
standing out as a blue background. Each field has an
area ratio of stained (red) versus non-stained (blue). A
final area ratio was obtained after averaging two fields.
To evaluate immunostaining intensity we used a
numeric score ranging from 0 to 3, reflecting the inten-
sity as follows: 0, no staining; 1, weak staining; 2, mod-
erate staining; and 3, intense staining. Using an Excel
spreadsheet, the mean score was obtained by multiply-
ing the intensity score (I) by the percentage of stained
cells [14] and the results were added together (total
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score: I × PC). This overall score was then averaged
with the number of cores that were analyzed for each
patient. If there was no tumor in a particular core, then
no score was given. In addition, for each tumor, the
mean score of two core biopsies was calculated.
Five fields per core, corresponding to areas of higher
immunostaining and without necrosis, were evaluated
for CD34, with a final area of 1 mm2. If there was no
tumor in a particular core, ten fields were evaluated in
another one in order to obtain the same final area. We
obtain a total score and this is the value of MVD in
each tumor.
Staining for ERs and PgRs was scored according to the
method described by Allred et al. [15]. p53 was assessed
by the number of positively stained nuclei, with greater
than 25% of stained cells indicating a positive result.
The HER-2 staining was made by immunohistochemis-
try with rabbit polyclonal antibody from Dako and for
the assessment we use the Herceptest scoring guidelines.
According to that a tumor was reported 2+ when a
weak to moderate complete membrane staining is
observed in > 10% of tumor cells. These cases were clas-
sified as equivocal and required confirmation by FISH
and a tumor was reported 3+ when a strong complete
membrane staining is observed in > 10% of tumor cells.
These cases were classified as positives and confirmation
was not required. Ki-67 (MIB-1) was assessed by the
number of positively stained nuclei, with greater than
10% of cells staining indicating a positive result. Con-
trols included breast cancer tissue with known immu-
noreactivity for each antibody used in the study.
Negative controls had the primary antibody omitted and
replaced by Antibody Diluent (Dako, Glostrup,
Denmark).
Data analysis and statistical methods
Patients were subdivided into groups based on different
clinical and pathological parameters, such as age, meno-
pausal status, tumor size, nodal status, histological
grade, desmoplastic reaction, tumor advancing ege, vas-
cular invasion, perineural invasion, necrosis, mitotic
index o peritumor inflammation. Differences in percen-
tages were calculated with the chi-square test and Yates’
correction when necessary. For quantitative comparison,
levels of these biological parameters were expressed as a
mean or a median (range). We analyzed the distribution
of variables by the Kolmogorov-Smirnov test. On the
base of this analysis, parametric methods (unpaired Stu-
dent’s and ANOVA tests) or non-parametric rank meth-
ods (Mann-Whitney and Kruskal-Wallis tests) were used
for comparison between groups of patients. The SPSS
11.5 program (SPSS Inc, Chicago, IL, USA) was used for
all calculations.
Results
In overall, using ACR BI-RADS MR lexicon, a total of
19 cases were BI-RAD 4 and 49 cases were BI-RAD 5
III [16]. The MRI parameters obtained from the breast
carcinomas included in the present study are shown in
Table 1. Four cases showed a regional non-nodular
enhancement, so the morphological features were only
analyzed in 64 cases, whereas the kinetic features in all
68 cases. These parameters included: mass margins,
internal mass enhancement, as well as kinetic character-
istics such as time of peak of maximum enhancement,
percentage of maximum enhancement before 2 min,
and type of enhancement curve. As can be seen in the
table, the majority of tumors showed an irregular or spi-
culated mass margin (75%), and a heterogeneous or rim
internal mass enhancement (81,2%). Nevertheless, it is
remarkable that homogeneous enhancement cases were
only observed in T1 (<2 cm in size) tumors (28.6%),
whereas none of the ≥ T2 tumors (≥ 2 cm) showed this
finding (p = 0.015). Only 2 (3.1%) tumors showed rim
enhancement. Likewise, the peak of maximum enhance-
ment was more frequently shown by tumors after two
min (75%), and a type III curve was shown by a higher
percentage of cases (type I curve, 7.3%; type II, 35.3%;
and type III, 57.4%). However, there was not a clear pre-
dominance in the percentage of maximum enhancement
among tumors before two minutes.
Table 2 shows the relationship between morphological
features, kinetic patterns of enhancement and the count
of intratumoral microvessel density (MVD), by using
immunostaining with anti-CD34. Tumors with irregular
of spiculated mass margin had a significant higher MVD
than tumors with smooth margin (p = 0.038). Likewise,
we found that tumors showing a maximum enhance-
ment peak at two minutes or longer, had a significant
higher MVD count than those ones that reached this
maximum point before two minutes (p = 0.012). Figure
1 shows representative examples of these associations.
Table 1 also shows the relationship between morpho-
logical features, kinetic pattern of enhancement and
clinicopathological patient and tumor characteristics.
Among all these factors, we found significant associa-
tions of MRI parameters with vascular invasion, mitotic
index and peritumor inflammation. The percentage of
tumors with vascular invasion or with high mitotic
index was significantly superior among those showing a
low percentage of maximum enhancement (≤ 150%)
before two minutes than in those showing a high per-
centage (>150%) of enhancement rate at that time inter-
val (p = 0.016 and p = 0.03, respectively). However, in
contrast, there was a significant and positive association
between the rate of mitotic index and the peak of maxi-
mum enhancement before two minuets (p = 0.036).
Fernández-Guinea et al. BMC Cancer 2010, 10:8
http://www.biomedcentral.com/1471-2407/10/8
Page 5 of 12
Moreover, the percentage of tumors with peritumor
inflammation was considerably higher in those showing
type III curves than in those with either types I or II
curves (p = 0.042), as well as when we compared both
type I and type II with type III (p = 0.035). Figure 2
shows representative examples of this association. On
the other hand, our results did not show significant
associations between the different MRI parameters and
menopausal status, nodal status, histotologial grade
(Table 1), patient’s age, desmoplastic reaction, tumor
advancing edge, perineural invasion, necrosis, histologi-
cal type, nuclear grade or DCIS associated component
(data not shown).
In the present study we also analyzed the possible
relationship between morphological features, kinetic pat-
terns of enhancement and some biological parameters of
interest in breast cancer, such as ER, PgR, p53, ki67,
HER2, VEGFR-1 and 2. However, as Table 3 demon-
strates, our results did not show any significant associa-
tion between the MRI parameters and any of these
biological factors.
Discussion
To evaluate the relationship between kinetic patterns
and either clinical or biological variables, we chose the
zones of maximum intensity of enhancement as areas of
interest. We found significant associations of these MRI
parameters with histopathological factors indicative of
tumor aggressiveness, suggesting that the preoperative
MRI may provide us with clinically useful information
in invasive breast cancer.
It was of note that homogeneous enhancement was
only observed in tumors smaller than 2 cm (T1),
whereas none of the T2 tumors greater than 2 cm (≥
T2) showed this pattern of enhancement. This finding
may be because larger size tumors (≥ T2) are biologi-
cally more heterogeneous lesions than T1 tumors.
Our results are in accordance with those of other
authors that reported that classical prognostic factors,
such as nodal status, tumor grading or hormone recep-
tor status, do not correlate with MRI parameters in
invasive breast cancer [17,18]. These findings seem to
indicate that MRI could provide complementary prog-
nostic to those provided by the classical factors. Like-
wise, our results did not show any significant
associations between MRI findings and molecular para-
meters of interest in breast cancer, such as HER2, p53,
ki67, and VEGFR-1 and 2. These latter findings could
signify that MRI reflects a biological behaviour of breast
carcinomas somehow not related to those molecular fac-
tors. Nevertheless, in the present study we have found
significant and positive associations of MRI with several
histopathological parameters of interest, such as MVD,
peritumor inflammation, vascular invasion, and mitotic
index. Some authors reported correlation of histological
grade to enhancement pattern [10,19]. We also found
higher kinetic features in grade I tumors than in grade
III tumors, such as peak of maximum enhancement <2’
of type III curve. However, the differences in these para-
meters did not achieve significant differences. We con-
sider that this may be due to the small size of sample
for this comparison as well as to the known inter-obser-
ver variation in histological grade evaluation [20,21].
It has been postulated that the rapid enhancement
demonstrated by breast carcinomas after administration
of contrast media is a direct result of tumor angiogen-
esis. MVD reflects the angiogenesis activity which con-
stitutes a prerequisite for the growth of malignant
tumors greater than 2 millimetres. MVD is considered a
significant although weak prognostic factor in breast
cancer. In the present study, we have found a variability
of MVD among tumors, which appears to correspond to
their biological heterogeneity. In addition, our data
show that intratumor MVD was significantly associated
with irregular mass margin as well as a maximum peak
Table 2 Relationship between morphological features,
kinetic patterns of enhancement and the count of
intratumor microvessel density (MVD)
RM features N° MVD
Mean (range)
p
64
Morphological
features
Margin 0.038
Well defined 16 21.8 (4.9-54.4)
Irregular/Spiculated 48 32.9 (5.2-140.6)
Enhancement
internal
n.s.
Homogeneous 12 19.5 (4.9-63.2)
Heterogeneous/
Rim
52 32.6 (5.2-140.6)
Kinetic features 68
Peak of maximum
enhancement
0.012
< 2’ 17 20.8 (8-54.4)
≥ 2’ 51 33.6 (4.9-140.6)
% of maximun
enhancement < 2’
n.s.
≤ 150% 39 31.2 (4.9-140.6)
> 150% 29 29.3 (5.2-96.5)
Curve type n.s.
I 5 36.5 (16.3-60.5)
II 24 29.6 (4.9-96.5)
III 39 30.1 (8-140.6)
* Four cases showed a non-nodular enhancement, so the morphological
features were analyzed in only 64 cases, and the kinetic features in all 68
cases.
Abbreviations: MVD, microvessel density; n.s, not significant.
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Figure 1 Breast MR image acquired in a 50-years-old patient with a palpable mass in the right inferior outer quadrant. The axial
postcontrast subtracted image (9.9/4.2; flip angle, 10°) depicts a lesion with spiculated margin of mass (arrow). The time-signal intensity curve of
this shows a type III time course with a peak of maximal enhancement after two min. (A). Immunohistochemical staining of CD34 in the same
tumor showing a high microvessel density. 100×. (B). Breast MR image acquired in a 63-years-old patient with a palpable mass in the left upper
inner quadrant. The axial postcontrast subtracted image (9.9/4.2; flip angle, 10°) depicts a lesion with smooth margin of mass (arrow). The time-
signal intensity curve of this shows a type III time course with a peak of maximal enhance before 2 min (C). Immunohistochemical staining of
CD34 in the same tumor showing a low microvessel density. 100×. (D).
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Figure 2 Breast MR image acquired in a 45-years-old patient with a palpable mass in the left upper outer quadrant. The axial
postcontrast subtracted image (9.9/4.2; flip angle, 10°) depicts a lesion with irregular margin of mass and heterogeneous enhancement (arrow).
The time-signal intensity curve of this shows a type III (washout) curve. (A). Microphotography of the same tumor showing a peritumoral
inflammation (arrows). 200×. (B). Breast MR image acquired in a 63-years-old patient with a palpable mass in the left upper outer quadrant. The
axial postcontrast subtracted image (9.9/4.2; flip angle, 10°) depicts a lesion of irregular margin of mass (arrow). The time-signal intensity curve of
this shows a type I curve. (C). Microphotography of the same tumor showing no a peritumoral inflammation. 100×. (D).
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after 2 min. It seems reasonable that there is an associa-
tion of high MVD with irregular margin since this mor-
phology is associated with a more aggressive behaviour
in breast cancer. However, the positive association
between MVD and delay in the maximal peak of
enhancement is a new finding. Some authors [22,23]
have described a correlation of initial enhancement with
MVD, but in more recent studies [24] this association
could not be demonstrated. Nevertheless, it is important
to consider that the divergent results may be a conse-
quence of differences in the techniques of microvessel
quantification as well as differences in the investigated
tumor area. This latter aspect is important especially for
a tumor showing heterogeneous enhancement. It is
known that there may be discrepancies in MVD estima-
tion when it is evaluated in the periphery or in the cen-
tre of the tumors. Thus, for example, it has been
recently reported that the characteristic enhancement in
the periphery of breast carcinomas at MRI is not caused
by an elevated MVD in the tumor periphery but rather
by a lower MVD in the tumor center [25]. We have
analyzed the areas of higher MVD, by immunostining
with anti-CD34, in the tumoral center, and these were
correlated with the area that exhibits strongest enhance-
ment on the first post-contrast image. Therefore, we
consider that our finding may be because the highest
MVD delayed the display of the maximum enhancement
capacity of the tumors. This may be because the para-
magnetic contrast spends more time in to fill in the
very vascularized tumors. Thus, this date might contri-
bute to the preoperative assessment of tumor angiogen-
esis, being potentially useful in selecting patients as
candidates for new therapies based on the available anti-
angiogenic strategies. Nevertheless, it is also known that
tumor enhancement in MRI may be influenced by sev-
eral factors, in addition to the extent and pattern of vas-
cularization, such as vessel permeability, cellularity,
interstitial pressure, and the fraction of the extracellular
space [26]. As mentioned before, we have also analyzed
the possible relationship between MRI parameters and
the expression of both VEGFR-1 and 2 in breast carci-
nomas. These two tyrosine kinase receptors are the
major mediators of the mitogenic and permeability-
enhancing effects of vascular endothelial growth factor
(VEGF) on cells. VEGF acts as a potent and selective
endothelial mitogen, inducing a rapid and complete
angiogenic response [27]. In addition, there are data
suggesting that VEGF expression is associated with con-
trast diffusion [9]. However, our results did not show
any significant associations between these growth-recep-
tor expressions and MRI parameters.
Angiogenesis is necessary for a tumor to grow but not
sufficient for it metastasize. There are biological differ-
ences between the ability of tumors to develop advanced
neovascularization and their ability to invade blood ves-
sels, this latter one being recognized as a more potent
prognostic factor of poor outcome in breast cancer. In
fact, in the present study we did not find any significant
differences in MVD count between tumors with vascular
invasion (mean MVD: 29.8 (range: 4.9-66.3)) and those
without vascular invasion (30.9(5.2-146)). In this study,
vascular invasion was defined as either the presence of
neoplastic cells with fibrin clots, erythrocytes, or both
within an endothelial-lined space without erythrocyte
extravasation into the surrounding tissue or by the pre-
sence of neoplastic cells within a smooth muscle cell-
lined space. Furthermore, we confirmed additional
immunostaining with anti-CD34 as a pan-endothelial
marker. Our results showed that the vascular invasion
and a high mitotic index were significantly and posi-
tively associated with a low percentage of maximum
enhancement (≤ 150%) before two minutes. These asso-
ciations may be explained due a lower number of func-
tional vessels because the occupation of these ones by
cancerous cells with high proliferate rate, which prevent
a fast passage of paramagnetic contrast. Even so, our
data suggest a value for the dynamic MRI in assessing
the metastatic potential of breast carcinomas. In con-
trast, there was a significant and positive association
between the rate of mitotic index and the peak of maxi-
mum intensity before two minutes, which is in accor-
dance with previous studies reporting a positive
association between MRI parameters and other prolif-
erative parameters, such as high DNA S-phase percen-
tage [28] or proliferative cellular activity as shown by
proliferative nuclear antigen (PCNA) immunoreactivity
[22]. Therefore our data appears to indicate that the
proliferative activity and the invasive potential of cancer-
ous cells could be, at least partially, unrelated processes.
We also consider remarkable our finding of a signifi-
cant relationship between peritumor inflammation and
signal-intensity curves type III. Mononuclear inflamma-
tory cells may account for as much as 50% of the total
tumor mass in some invasive carcinomas. Historically,
tumor-infiltrating leukocytes have been considered to be
manifestations of an intrinsic defence mechanism
against tumor development [29]. However, there are
data indicating that leukocyte infiltration might promote
tumor phenotypes, such as angiogenesis, growth, and
invasion [30]. This may be because inflammatory cells
probably influence cancer promotion by secreting cyto-
kines, growth factors, chemokines and proteases, stimu-
lating proliferation and invasiveness of cancerous cells
[31]. This association between peritumor inflammation
and a type III curve is, to the best of our knowledge, a
new finding. A time course curve type III is a strong
indicator of malignancy and is independent of other cri-
teria [5]. In addition, the detection of a washout
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phenomenon suggests the presence of an increased ves-
sel density and arterio-venous anastomoses with rapid
outflow and thus fading of the contrast material [23].
Therefore, our finding may to contribute to the charac-
terization of the possible biological influence of infiltrat-
ing mononuclear inflammatory cells in breast cancer.
Limitation of the present study is the difficult to asses
exactly the tumor localization evaluated by MRI and his-
tologically. Nevertheless, we consider that we performed
a reasonable correlation between both types of evalua-
tions. Certainly there are other possible parameters for
evaluating MRI and both histological and biological
aspects of breast carcinomas, which should be investi-
gated in futures studies. In addition, prospective studies
are necessary to asses the potential value of MRI para-
metrers as prognostic factors in breast cancer.
Conclusions
In conclusion, especially relevant are our findings that
variations in the dynamic MRI parameters seem to be
associated with parameters indicatives of tumor aggres-
siveness, such as high MVD count, vascular invasion,
high mitotic index in breast cancer or peritumor inflam-
mation. Therefore, our results are in accordance with
previous report indicating the potential value of dynamic
MRI for better characterizing breast cancer.
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